At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01911 CR HOLDINGS
Trading 04-23 09:40:52
3.570
-0.060
-1.65%
High3.630Low3.570Vol12.80K
Open3.630D1 Closing3.630Amplitude1.65%
Mkt Cap2.05BTradable Cap2.05BTotal Shares573.00M
T/O46.44KT/O Rate0.00%Tradable Shares573.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Innovent advances IBI363 into phase 3 MarsLight-11 trial in squamous NSCLC
Reuters  ·  04-22 08:00
Innovent advances IBI363 into phase 3 MarsLight-11 trial in squamous NSCLC
Innovent presents preclinical data on IBI3055 at Immune Resetting Summit 2026
Reuters  ·  04-10
Innovent presents preclinical data on IBI3055 at Immune Resetting Summit 2026
China Renaissance Holdings SEHK 1911 Return To Profit Tests Longstanding Bearish Earnings Narratives
Simply Wall St.  ·  04-01
China Renaissance Holdings SEHK 1911 Return To Profit Tests Longstanding Bearish Earnings Narratives
CR Holdings Posts Stable Share Capital in March; 573.35 Million Shares Outstanding, No New Issuances
Bulletin Express  ·  04-01
CR Holdings Posts Stable Share Capital in March; 573.35 Million Shares Outstanding, No New Issuances
Innovent partner Ollin says OLN324 beats Roche’s Vabysmo on DME anatomy in Phase 1b trial
Reuters  ·  03-31
Innovent partner Ollin says OLN324 beats Roche’s Vabysmo on DME anatomy in Phase 1b trial
Innovent Biologics grants 10.2 million restricted shares under 2024 share scheme
Reuters  ·  03-31
Innovent Biologics grants 10.2 million restricted shares under 2024 share scheme
BRIEF-China Renaissance Logs FY Profit Attributable RMB101.4 Mln
Reuters  ·  03-30
BRIEF-China Renaissance Logs FY Profit Attributable RMB101.4 Mln
CR HOLDINGS (01911) Reports Annual Results: Turns to Profit with RMB 101 Million Attributable to Owners
Stock News  ·  03-30
CR HOLDINGS (01911) Reports Annual Results: Turns to Profit with RMB 101 Million Attributable to Owners
China Renaissance - FY Total Revenue RMB1.07 Bln
THOMSON REUTERS  ·  03-30
China Renaissance - FY Total Revenue RMB1.07 Bln
China Renaissance FY25 profit attributable to owners swings to RMB 101m; revenue rises 37.2% to RMB 1.1bn
Reuters  ·  03-30
China Renaissance FY25 profit attributable to owners swings to RMB 101m; revenue rises 37.2% to RMB 1.1bn
BUZZ-Innovent Biologics set for biggest jump in 5 months on FY revenue growth
Reuters  ·  03-27
BUZZ-Innovent Biologics set for biggest jump in 5 months on FY revenue growth
Innovent Biologics FY2025 non-IFRS profit jumps to RMB 1.7 billion; revenue rises 38.4% to RMB 13 billion
Reuters  ·  03-26
Innovent Biologics FY2025 non-IFRS profit jumps to RMB 1.7 billion; revenue rises 38.4% to RMB 13 billion
Innovent clarifies Lilly collaboration is not an acquisition
Reuters  ·  03-25
Innovent clarifies Lilly collaboration is not an acquisition
Innovent Phase 3 STAR trial shows efdamrofusp alfa meets primary endpoint in nAMD with 72.8% at Q16W dosing
Reuters  ·  03-24
Innovent Phase 3 STAR trial shows efdamrofusp alfa meets primary endpoint in nAMD with 72.8% at Q16W dosing
Innovent doses first patient in 600-participant Phase 3 IBI128 gout trial versus febuxostat
Reuters  ·  03-23
Innovent doses first patient in 600-participant Phase 3 IBI128 gout trial versus febuxostat
CR HOLDINGS (01911) Issues Profit Alert, Anticipates Annual Profit Attributable to Shareholders of Approximately RMB 101.4 Million, Turning Loss into Profit
Stock News  ·  03-20
CR HOLDINGS (01911) Issues Profit Alert, Anticipates Annual Profit Attributable to Shareholders of Approximately RMB 101.4 Million, Turning Loss into Profit
China Renaissance forecasts 2025 profit attributable to owners of RMB101.4 million
Reuters  ·  03-20
China Renaissance forecasts 2025 profit attributable to owners of RMB101.4 million
China Renaissance - Expected Result Driven by Investment Management Segment Gains in FY, Others
THOMSON REUTERS  ·  03-20
China Renaissance - Expected Result Driven by Investment Management Segment Gains in FY, Others
China Renaissance - Expects Profit Attributable of RMB101.4 Mln for Year
THOMSON REUTERS  ·  03-20
China Renaissance - Expects Profit Attributable of RMB101.4 Mln for Year
Innovent Biologics board to review annual results and consider final dividend recommendation
Reuters  ·  03-12
Innovent Biologics board to review annual results and consider final dividend recommendation

Introduction

Company Name.
CR HOLDINGS
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
China Renaissance Holdings Ltd is a holding company that is primarily engaged in providing investment banking and investment management services. The Company operates in four segments. Investment Banking segment provides early to late stage financial advisory and mergers and acquisitions advisory services, equity underwriting, sales, trading, brokerage, research services and structured financial services. Investment Management segment provides fund and asset management and manages its own investments in funds. China Renaissance (CR) Securities segment provides investment banking and asset management business. Others segment mainly includes wealth management business and investment and management of own funds.
Issue price:
--